DK2471954T3 - Susceptibility genetic variants associated with cardiovascular diseases - Google Patents

Info

Publication number

DK2471954T3

DK2471954T3 DK11194162.1T DK11194162T DK2471954T3 DK 2471954 T3 DK2471954 T3 DK 2471954T3 DK 11194162 T DK11194162 T DK 11194162T DK 2471954 T3 DK2471954 T3 DK 2471954T3

Authority

DK

Denmark

Prior art keywords

risk

markers

allele

disease

marker

Prior art date

2007-02-21

Links

• Espacenet
• Global Dossier
• Discuss

• 230000002068 genetic effect Effects 0.000 title description 84
• 208000024172 Cardiovascular disease Diseases 0.000 title description 18
• 108700028369 Alleles Proteins 0.000 claims description 313
• 200000000007 Arterial disease Diseases 0.000 claims description 205
• 238000000034 method Methods 0.000 claims description 156
• 239000003550 marker Substances 0.000 claims description 146
• 208000029078 coronary artery disease Diseases 0.000 claims description 144
• 241000282414 Homo sapiens Species 0.000 claims description 134
• 150000007523 nucleic acids Chemical class 0.000 claims description 128
• 102000039446 nucleic acids Human genes 0.000 claims description 116
• 108020004707 nucleic acids Proteins 0.000 claims description 116
• 208000007474 aortic aneurysm Diseases 0.000 claims description 109
• 208000037803 restenosis Diseases 0.000 claims description 64
• 208000006011 Stroke Diseases 0.000 claims description 57
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 55
• 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 53
• 208000010125 myocardial infarction Diseases 0.000 claims description 37
• 201000008450 Intracranial aneurysm Diseases 0.000 claims description 33
• 210000000349 chromosome Anatomy 0.000 claims description 31
• 108010074051 C-Reactive Protein Proteins 0.000 claims description 23
• 102100032752 C-reactive protein Human genes 0.000 claims description 23
• 230000002596 correlated effect Effects 0.000 claims description 23
• 150000002617 leukotrienes Chemical class 0.000 claims description 22
• 210000001519 tissue Anatomy 0.000 claims description 22
• 239000011159 matrix material Substances 0.000 claims description 20
• 102000005741 Metalloproteases Human genes 0.000 claims description 19
• 108010006035 Metalloproteases Proteins 0.000 claims description 19
• 239000000090 biomarker Substances 0.000 claims description 18
• 210000002966 serum Anatomy 0.000 claims description 16
• 230000002757 inflammatory effect Effects 0.000 claims description 14
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 13
• 230000000747 cardiac effect Effects 0.000 claims description 9
• 102000004889 Interleukin-6 Human genes 0.000 claims description 8
• 108090001005 Interleukin-6 Proteins 0.000 claims description 8
• 229940100601 interleukin-6 Drugs 0.000 claims description 8
• 108010049003 Fibrinogen Proteins 0.000 claims description 7
• 102000008946 Fibrinogen Human genes 0.000 claims description 7
• 102000003896 Myeloperoxidases Human genes 0.000 claims description 7
• 108090000235 Myeloperoxidases Proteins 0.000 claims description 7
• 206010028851 Necrosis Diseases 0.000 claims description 7
• 229940012952 fibrinogen Drugs 0.000 claims description 7
• 230000017074 necrotic cell death Effects 0.000 claims description 7
• 239000002207 metabolite Substances 0.000 claims description 6
• 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 5
• 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 5
• 108010024212 E-Selectin Proteins 0.000 claims description 5
• 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 claims description 5
• 108700028909 Serum Amyloid A Proteins 0.000 claims description 5
• 102000054727 Serum Amyloid A Human genes 0.000 claims description 5
• VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical group CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims description 5
• GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims description 5
• YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 5
• OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 claims description 5
• 210000005167 vascular cell Anatomy 0.000 claims description 5
• 102000007390 Glycogen Phosphorylase Human genes 0.000 claims description 2
• 108010046163 Glycogen Phosphorylase Proteins 0.000 claims description 2
• 102000004903 Troponin Human genes 0.000 claims description 2
• 108090001027 Troponin Proteins 0.000 claims description 2
• 238000000338 in vitro Methods 0.000 claims description 2
• 102000004420 Creatine Kinase Human genes 0.000 claims 1
• 108010042126 Creatine kinase Proteins 0.000 claims 1
• 102000015689 E-Selectin Human genes 0.000 claims 1
• 102000054766 genetic haplotypes Human genes 0.000 description 207
• 239000000523 sample Substances 0.000 description 159
• 108020004414 DNA Proteins 0.000 description 142
• 108090000623 proteins and genes Proteins 0.000 description 108
• 208000002223 abdominal aortic aneurysm Diseases 0.000 description 102
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 98
• 239000002773 nucleotide Substances 0.000 description 93
• 125000003729 nucleotide group Chemical group 0.000 description 93
• 201000010099 disease Diseases 0.000 description 90
• 108090000765 processed proteins & peptides Proteins 0.000 description 78
• 102000004196 processed proteins & peptides Human genes 0.000 description 77
• 229920001184 polypeptide Polymers 0.000 description 76
• 230000014509 gene expression Effects 0.000 description 74
• 206010002329 Aneurysm Diseases 0.000 description 57
• 238000012360 testing method Methods 0.000 description 55
• 238000011282 treatment Methods 0.000 description 54
• 239000003814 drug Substances 0.000 description 53
• 102000004169 proteins and genes Human genes 0.000 description 52
• 238000004458 analytical method Methods 0.000 description 50
• 239000003795 chemical substances by application Substances 0.000 description 43
• 230000000694 effects Effects 0.000 description 38
• 238000001514 detection method Methods 0.000 description 36
• 210000004027 cell Anatomy 0.000 description 34
• 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 32
• 230000003247 decreasing effect Effects 0.000 description 30
• 238000003745 diagnosis Methods 0.000 description 29
• 108091092878 Microsatellite Proteins 0.000 description 28
• 102000054765 polymorphisms of proteins Human genes 0.000 description 27
• 230000008439 repair process Effects 0.000 description 27
• 108020004999 messenger RNA Proteins 0.000 description 26
• 239000013615 primer Substances 0.000 description 26
• 239000000969 carrier Substances 0.000 description 25
• 238000009396 hybridization Methods 0.000 description 25
• 238000003752 polymerase chain reaction Methods 0.000 description 25
• 229940124597 therapeutic agent Drugs 0.000 description 25
• 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 24
• 230000000295 complement effect Effects 0.000 description 24
• 229940079593 drug Drugs 0.000 description 24
• 238000003556 assay Methods 0.000 description 22
• 239000000203 mixture Substances 0.000 description 22
• 230000006798 recombination Effects 0.000 description 22
• 238000005215 recombination Methods 0.000 description 22
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
• 230000010076 replication Effects 0.000 description 20
• 201000001320 Atherosclerosis Diseases 0.000 description 19
• 210000001367 artery Anatomy 0.000 description 19
• 230000000875 corresponding effect Effects 0.000 description 19
• 239000012634 fragment Substances 0.000 description 19
• 206010028980 Neoplasm Diseases 0.000 description 18
• 150000001413 amino acids Chemical group 0.000 description 18
• 239000000047 product Substances 0.000 description 18
• 208000024891 symptom Diseases 0.000 description 18
• 239000003153 chemical reaction reagent Substances 0.000 description 17
• 210000004369 blood Anatomy 0.000 description 16
• 239000008280 blood Substances 0.000 description 16
• 239000002131 composite material Substances 0.000 description 16
• 238000001356 surgical procedure Methods 0.000 description 16
• 238000002560 therapeutic procedure Methods 0.000 description 16
• 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 15
• 102000004190 Enzymes Human genes 0.000 description 15
• 108090000790 Enzymes Proteins 0.000 description 15
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 15
• 150000001875 compounds Chemical class 0.000 description 15
• 229940088598 enzyme Drugs 0.000 description 15
• 230000009368 gene silencing by RNA Effects 0.000 description 15
• 238000012163 sequencing technique Methods 0.000 description 15
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 14
• 108091028043 Nucleic acid sequence Proteins 0.000 description 14
• 230000003143 atherosclerotic effect Effects 0.000 description 14
• 239000002853 nucleic acid probe Substances 0.000 description 14
• 102100024462 Cyclin-dependent kinase 4 inhibitor B Human genes 0.000 description 13
• 230000004075 alteration Effects 0.000 description 13
• 230000000692 anti-sense effect Effects 0.000 description 13
• 210000000702 aorta abdominal Anatomy 0.000 description 13
• 230000027455 binding Effects 0.000 description 13
• 238000009739 binding Methods 0.000 description 13
• 238000003205 genotyping method Methods 0.000 description 13
• 210000002216 heart Anatomy 0.000 description 13
• 230000003902 lesion Effects 0.000 description 13
• 108091034117 Oligonucleotide Proteins 0.000 description 12
• 108020004459 Small interfering RNA Proteins 0.000 description 12
• 101710102803 Tumor suppressor ARF Proteins 0.000 description 12
• 238000002399 angioplasty Methods 0.000 description 12
• 230000015572 biosynthetic process Effects 0.000 description 12
• 201000011510 cancer Diseases 0.000 description 12
• 230000008859 change Effects 0.000 description 12
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
• 238000005516 engineering process Methods 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 230000001105 regulatory effect Effects 0.000 description 12
• 230000004044 response Effects 0.000 description 12
• 238000012502 risk assessment Methods 0.000 description 12
• 239000004055 small Interfering RNA Substances 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 239000013068 control sample Substances 0.000 description 11
• 239000003623 enhancer Substances 0.000 description 11
• 239000000463 material Substances 0.000 description 11
• 208000030613 peripheral artery disease Diseases 0.000 description 11
• 238000012217 deletion Methods 0.000 description 10
• 230000037430 deletion Effects 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 108700024394 Exon Proteins 0.000 description 9
• 206010020772 Hypertension Diseases 0.000 description 9
• 208000031481 Pathologic Constriction Diseases 0.000 description 9
• 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 239000002299 complementary DNA Substances 0.000 description 9
• 210000004351 coronary vessel Anatomy 0.000 description 9
• 230000007423 decrease Effects 0.000 description 9
• 238000013461 design Methods 0.000 description 9
• 238000003780 insertion Methods 0.000 description 9
• 230000037431 insertion Effects 0.000 description 9
• 238000012216 screening Methods 0.000 description 9
• 208000032382 Ischaemic stroke Diseases 0.000 description 8
• WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 8
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 8
• 108091093037 Peptide nucleic acid Proteins 0.000 description 8
• 238000012098 association analyses Methods 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• 210000004408 hybridoma Anatomy 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 239000002751 oligonucleotide probe Substances 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 238000012552 review Methods 0.000 description 8
• 230000036262 stenosis Effects 0.000 description 8
• 208000037804 stenosis Diseases 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 238000011277 treatment modality Methods 0.000 description 8
• 230000002792 vascular Effects 0.000 description 8
• 101710187011 Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• 208000007536 Thrombosis Diseases 0.000 description 7
• 230000003321 amplification Effects 0.000 description 7
• 210000003423 ankle Anatomy 0.000 description 7
• 210000000709 aorta Anatomy 0.000 description 7
• 238000004422 calculation algorithm Methods 0.000 description 7
• 230000036541 health Effects 0.000 description 7
• 239000003112 inhibitor Substances 0.000 description 7
• 238000011835 investigation Methods 0.000 description 7
• 150000002632 lipids Chemical class 0.000 description 7
• 238000012544 monitoring process Methods 0.000 description 7
• 238000003199 nucleic acid amplification method Methods 0.000 description 7
• 230000001681 protective effect Effects 0.000 description 7
• 238000010561 standard procedure Methods 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 6
• 108091027967 Small hairpin RNA Proteins 0.000 description 6
• 208000032109 Transient ischaemic attack Diseases 0.000 description 6
• 238000002725 brachytherapy Methods 0.000 description 6
• 238000002586 coronary angiography Methods 0.000 description 6
• 238000007887 coronary angioplasty Methods 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 238000009826 distribution Methods 0.000 description 6
• 238000002844 melting Methods 0.000 description 6
• 230000008018 melting Effects 0.000 description 6
• 239000002987 primer (paints) Substances 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000000391 smoking effect Effects 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 201000010875 transient cerebral ischemia Diseases 0.000 description 6
• 230000014616 translation Effects 0.000 description 6
• 102000053602 DNA Human genes 0.000 description 5
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• 206010061216 Infarction Diseases 0.000 description 5
• 206010061218 Inflammation Diseases 0.000 description 5
• 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 5
• 206010039330 Ruptured cerebral aneurysm Diseases 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 238000002583 angiography Methods 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 239000012472 biological sample Substances 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 230000002759 chromosomal effect Effects 0.000 description 5
• 238000002591 computed tomography Methods 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 230000007613 environmental effect Effects 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 230000007574 infarction Effects 0.000 description 5
• 230000004054 inflammatory process Effects 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 238000007726 management method Methods 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 238000004393 prognosis Methods 0.000 description 5
• 102210008529 rs10811661 Human genes 0.000 description 5
• 238000013517 stratification Methods 0.000 description 5
• 208000023516 stroke disease Diseases 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 102100023471 E-selectin Human genes 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 206010014498 Embolic stroke Diseases 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101000619898 Homo sapiens Leukotriene A-4 hydrolase Proteins 0.000 description 4
• 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 4
• 238000003657 Likelihood-ratio test Methods 0.000 description 4
• 238000007476 Maximum Likelihood Methods 0.000 description 4
• 208000008589 Obesity Diseases 0.000 description 4
• 108700026244 Open Reading Frames Proteins 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• 230000035508 accumulation Effects 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 229960001138 acetylsalicylic acid Drugs 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 238000003491 array Methods 0.000 description 4
• 208000028922 artery disease Diseases 0.000 description 4
• 230000001269 cardiogenic effect Effects 0.000 description 4
• 230000003412 degenerative effect Effects 0.000 description 4
• 238000003197 gene knockdown Methods 0.000 description 4
• 230000030279 gene silencing Effects 0.000 description 4
• 230000007614 genetic variation Effects 0.000 description 4
• 239000001257 hydrogen Substances 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 235000020824 obesity Nutrition 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• 230000035882 stress Effects 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 206010002388 Angina unstable Diseases 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 102400000432 CD40 ligand, soluble form Human genes 0.000 description 3
• 101800000267 CD40 ligand, soluble form Proteins 0.000 description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• -1 CysLTRI Proteins 0.000 description 3
• 208000005189 Embolism Diseases 0.000 description 3
• 108010042407 Endonucleases Proteins 0.000 description 3
• 102000004533 Endonucleases Human genes 0.000 description 3
• 238000000729 Fisher's exact test Methods 0.000 description 3
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 3
• 206010071602 Genetic polymorphism Diseases 0.000 description 3
• 108010007622 LDL Lipoproteins Proteins 0.000 description 3
• 102000007330 LDL Lipoproteins Human genes 0.000 description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
• 208000018262 Peripheral vascular disease Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• 208000007814 Unstable Angina Diseases 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 239000000074 antisense oligonucleotide Substances 0.000 description 3
• 238000012230 antisense oligonucleotides Methods 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 239000002876 beta blocker Substances 0.000 description 3
• 229940097320 beta blocking agent Drugs 0.000 description 3
• 238000011325 biochemical measurement Methods 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 210000001715 carotid artery Anatomy 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 210000001627 cerebral artery Anatomy 0.000 description 3
• 208000026106 cerebrovascular disease Diseases 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 235000012000 cholesterol Nutrition 0.000 description 3
• 210000000275 circle of willis Anatomy 0.000 description 3
• 230000004087 circulation Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 238000002405 diagnostic procedure Methods 0.000 description 3
• 230000029087 digestion Effects 0.000 description 3
• 230000010339 dilation Effects 0.000 description 3
• 238000002283 elective surgery Methods 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000007850 fluorescent dye Substances 0.000 description 3
• 230000037433 frameshift Effects 0.000 description 3
• 238000012226 gene silencing method Methods 0.000 description 3
• 230000009395 genetic defect Effects 0.000 description 3
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
• 238000003384 imaging method Methods 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000007917 intracranial administration Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 239000002679 microRNA Substances 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 238000002966 oligonucleotide array Methods 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 230000003449 preventive effect Effects 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 239000012857 radioactive material Substances 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 229940126586 small molecule drug Drugs 0.000 description 3
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 238000001308 synthesis method Methods 0.000 description 3
• 210000002700 urine Anatomy 0.000 description 3
• 208000019553 vascular disease Diseases 0.000 description 3
• FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 2
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
• VPTONMHDLLMOOV-UHFFFAOYSA-N 4-[3-[4-(2-methylimidazol-1-yl)phenyl]sulfanylphenyl]oxane-4-carboxamide Chemical compound CC1=NC=CN1C(C=C1)=CC=C1SC1=CC=CC(C2(CCOCC2)C(N)=O)=C1 VPTONMHDLLMOOV-UHFFFAOYSA-N 0.000 description 2
• 208000035657 Abasia Diseases 0.000 description 2
• 206010000077 Abdominal mass Diseases 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
• 206010003658 Atrial Fibrillation Diseases 0.000 description 2
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
• 206010008479 Chest Pain Diseases 0.000 description 2
• 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 208000032170 Congenital Abnormalities Diseases 0.000 description 2
• 201000000054 Coronary Restenosis Diseases 0.000 description 2
• 201000000057 Coronary Stenosis Diseases 0.000 description 2
• 206010011086 Coronary artery occlusion Diseases 0.000 description 2
• 206010056489 Coronary artery restenosis Diseases 0.000 description 2
• 108020003215 DNA Probes Proteins 0.000 description 2
• 239000003298 DNA probe Substances 0.000 description 2
• 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 101000978210 Homo sapiens Leukotriene C4 synthase Proteins 0.000 description 2
• 101000589859 Homo sapiens Prostaglandin reductase 1 Proteins 0.000 description 2
• 208000035150 Hypercholesterolemia Diseases 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 206010022562 Intermittent claudication Diseases 0.000 description 2
• 206010059491 Intracranial haematoma Diseases 0.000 description 2
• 238000008214 LDL Cholesterol Methods 0.000 description 2
• 102100023758 Leukotriene C4 synthase Human genes 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 208000034827 Neointima Diseases 0.000 description 2
• 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 2
• 108020004485 Nonsense Codon Proteins 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 206010034576 Peripheral ischaemia Diseases 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 102100032258 Prostaglandin reductase 1 Human genes 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 238000010802 RNA extraction kit Methods 0.000 description 2
• 208000004717 Ruptured Aneurysm Diseases 0.000 description 2
• 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
• 206010047139 Vasoconstriction Diseases 0.000 description 2
• 206010047163 Vasospasm Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
• 229940030600 antihypertensive agent Drugs 0.000 description 2
• 239000002220 antihypertensive agent Substances 0.000 description 2
• 229940127218 antiplatelet drug Drugs 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 238000009530 blood pressure measurement Methods 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 239000003560 cancer drug Substances 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• 238000000546 chi-square test Methods 0.000 description 2
• 235000019365 chlortetracycline Nutrition 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 229960003009 clopidogrel Drugs 0.000 description 2
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 238000005520 cutting process Methods 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 239000002934 diuretic Substances 0.000 description 2
• 229940030606 diuretics Drugs 0.000 description 2
• 238000007876 drug discovery Methods 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 230000003628 erosive effect Effects 0.000 description 2
• NBVALOWOMUMEJI-UHFFFAOYSA-N ethyl 1-[2-(4-benzylphenoxy)ethyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1CCOC(C=C1)=CC=C1CC1=CC=CC=C1 NBVALOWOMUMEJI-UHFFFAOYSA-N 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 238000010195 expression analysis Methods 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 210000001105 femoral artery Anatomy 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 238000003209 gene knockout Methods 0.000 description 2
• 102000054767 gene variant Human genes 0.000 description 2
• 238000012252 genetic analysis Methods 0.000 description 2
• 210000003090 iliac artery Anatomy 0.000 description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000037353 metabolic pathway Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 230000000869 mutational effect Effects 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 230000002974 pharmacogenomic effect Effects 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 238000011176 pooling Methods 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 230000004853 protein function Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 238000003753 real-time PCR Methods 0.000 description 2
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 230000000250 revascularization Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 102210044018 rs2069426 Human genes 0.000 description 2
• 102210046871 rs3217992 Human genes 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 230000004960 subcellular localization Effects 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 208000024535 susceptibility to myocardial infarction Diseases 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 238000002604 ultrasonography Methods 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 230000025033 vasoconstriction Effects 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 210000002385 vertebral artery Anatomy 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• ZEYYDOLCHFETHQ-JOCHJYFZSA-N (2r)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical compound C1([C@@H](C(=O)O)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CCCC1 ZEYYDOLCHFETHQ-JOCHJYFZSA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• MMSNEKOTSJRTRI-LLVKDONJSA-N 1-[(2r)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea Chemical compound S1C(C#C[C@@H](C)N(O)C(N)=O)=CC=C1CC1=CC=C(F)C=C1 MMSNEKOTSJRTRI-LLVKDONJSA-N 0.000 description 1
• OUHAMHSISQCVQY-UHFFFAOYSA-N 1-[2-(4-benzylphenoxy)ethyl]-2-methyl-4-(2h-tetrazol-5-yl)piperidine Chemical compound CC1CC(C=2NN=NN=2)CCN1CCOC(C=C1)=CC=C1CC1=CC=CC=C1 OUHAMHSISQCVQY-UHFFFAOYSA-N 0.000 description 1
• FLQWALQQHUBJRM-UHFFFAOYSA-N 1-[2-(4-benzylphenoxy)ethyl]-4-(2h-tetrazol-5-yl)piperidine Chemical compound C=1C=C(CC=2C=CC=CC=2)C=CC=1OCCN(CC1)CCC1C1=NN=NN1 FLQWALQQHUBJRM-UHFFFAOYSA-N 0.000 description 1
• ZWKZBIUABHACKJ-UHFFFAOYSA-N 2,3-dihydroxypropyl nitrate 1,3-dinitrooxypropan-2-yl nitrate Chemical compound OCC(O)CO[N+]([O-])=O.[O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O ZWKZBIUABHACKJ-UHFFFAOYSA-N 0.000 description 1
• PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
• GJCFOZVWBUJKNH-UHFFFAOYSA-N 2-[4-[5-(3-phenylpropyl)thiophen-2-yl]butoxy]acetic acid Chemical compound S1C(CCCCOCC(=O)O)=CC=C1CCCC1=CC=CC=C1 GJCFOZVWBUJKNH-UHFFFAOYSA-N 0.000 description 1
• IUWJOVIQIJRTOX-UHFFFAOYSA-N 3-[3-[4-(4-fluorophenoxy)phenoxy]propyl-methylamino]propanoic acid Chemical compound C1=CC(OCCCN(C)CCC(O)=O)=CC=C1OC1=CC=C(F)C=C1 IUWJOVIQIJRTOX-UHFFFAOYSA-N 0.000 description 1
• WXPJULBDMSVCLI-UHFFFAOYSA-N 3-[methyl-[3-[4-(4-phenylphenoxy)phenoxy]propyl]amino]propanoic acid Chemical compound C1=CC(OCCCN(C)CCC(O)=O)=CC=C1OC1=CC=C(C=2C=CC=CC=2)C=C1 WXPJULBDMSVCLI-UHFFFAOYSA-N 0.000 description 1
• GMDFARFIYKWUOZ-UHFFFAOYSA-N 3-[methyl-[3-[4-(thiophen-2-ylmethyl)phenoxy]propyl]amino]propanoic acid Chemical compound C1=CC(OCCCN(C)CCC(O)=O)=CC=C1CC1=CC=CS1 GMDFARFIYKWUOZ-UHFFFAOYSA-N 0.000 description 1
• WSHWIOIPTHKMJC-UHFFFAOYSA-N 3-[methyl-[3-[4-(thiophen-3-ylmethyl)phenoxy]propyl]amino]propanoic acid Chemical compound C1=CC(OCCCN(C)CCC(O)=O)=CC=C1CC1=CSC=C1 WSHWIOIPTHKMJC-UHFFFAOYSA-N 0.000 description 1
• FJJNICCLRJKQKS-KRWDZBQOSA-N 4-[(2s)-2-[[4-(4-chlorophenoxy)phenoxy]methyl]pyrrolidin-1-yl]butanamide Chemical group NC(=O)CCCN1CCC[C@H]1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 FJJNICCLRJKQKS-KRWDZBQOSA-N 0.000 description 1
• 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
• 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
• 102100033639 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• FDQGNLOWMMVRQL-UHFFFAOYSA-N Allobarbital Chemical compound C=CCC1(CC=C)C(=O)NC(=O)NC1=O FDQGNLOWMMVRQL-UHFFFAOYSA-N 0.000 description 1
• 206010059245 Angiopathy Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 206010058178 Aortic occlusion Diseases 0.000 description 1
• 102100029470 Apolipoprotein E Human genes 0.000 description 1
• 101710095339 Apolipoprotein E Proteins 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 206010060965 Arterial stenosis Diseases 0.000 description 1
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
• 206010003225 Arteriospasm coronary Diseases 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 238000012935 Averaging Methods 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 208000016216 Choristoma Diseases 0.000 description 1
• 244000175448 Citrus madurensis Species 0.000 description 1
• 235000004332 Citrus madurensis Nutrition 0.000 description 1
• 235000007438 Citrus mitis Nutrition 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 101150011616 Ctcf gene Proteins 0.000 description 1
• 102100033539 Cysteinyl leukotriene receptor 2 Human genes 0.000 description 1
• 108090000655 Cysteinyl leukotriene receptor 2 Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 239000003155 DNA primer Substances 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• 206010051055 Deep vein thrombosis Diseases 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 206010014476 Elevated cholesterol Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 102000008857 Ferritin Human genes 0.000 description 1
• 108050000784 Ferritin Proteins 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 208000002513 Flank pain Diseases 0.000 description 1
• 240000005702 Galium aparine Species 0.000 description 1
• 235000014820 Galium aparine Nutrition 0.000 description 1
• 206010017711 Gangrene Diseases 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• 206010018735 Groin pain Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 108091027305 Heteroduplex Proteins 0.000 description 1
• 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
• 101100455054 Homo sapiens LTA4H gene Proteins 0.000 description 1
• 101100236208 Homo sapiens LTB4R gene Proteins 0.000 description 1
• 101001017969 Homo sapiens Leukotriene B4 receptor 2 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 108010028554 LDL Cholesterol Proteins 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 1
• 102100033375 Leukotriene B4 receptor 2 Human genes 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 241000997826 Melanocetus johnsonii Species 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 101001034845 Mus musculus Interferon-induced transmembrane protein 3 Proteins 0.000 description 1
• 102000010645 MutS Proteins Human genes 0.000 description 1
• 108010038272 MutS Proteins Proteins 0.000 description 1
• YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 102400000058 Neuregulin-1 Human genes 0.000 description 1
• 108090000556 Neuregulin-1 Proteins 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000364051 Pima Species 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 1
• 101710156627 Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 208000032236 Predisposition to disease Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 208000030555 Pygmy Diseases 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
• 101100075025 Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-11545) LTA4 gene Proteins 0.000 description 1
• 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 description 1
• 208000010340 Sleep Deprivation Diseases 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 208000007718 Stable Angina Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 241000282485 Vulpes vulpes Species 0.000 description 1
• DUDJTRNGXIUJEB-UHFFFAOYSA-N [N].NCC(O)=O Chemical group [N].NCC(O)=O DUDJTRNGXIUJEB-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 206010000891 acute myocardial infarction Diseases 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 229940030613 agent acting on the renin-angiotensin system Drugs 0.000 description 1
• 239000002170 aldosterone antagonist Substances 0.000 description 1
• 229940083712 aldosterone antagonist Drugs 0.000 description 1
• 238000007844 allele-specific PCR Methods 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• 210000004381 amniotic fluid Anatomy 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003172 anti-dna Effects 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000003276 anti-hypertensive effect Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000036523 atherogenesis Effects 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 229950010288 atreleuton Drugs 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 201000005008 bacterial sepsis Diseases 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 235000021028 berry Nutrition 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 238000007622 bioinformatic analysis Methods 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 208000021138 brain aneurysm Diseases 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 239000003710 calcium ionophore Substances 0.000 description 1
• 210000001054 cardiac fibroblast Anatomy 0.000 description 1
• 229940097217 cardiac glycoside Drugs 0.000 description 1
• 239000002368 cardiac glycoside Substances 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 210000004004 carotid artery internal Anatomy 0.000 description 1
• 229960004195 carvedilol Drugs 0.000 description 1
• NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000032677 cell aging Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000003727 cerebral blood flow Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 210000004298 cerebral vein Anatomy 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000012707 chemical precursor Substances 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 208000024980 claudication Diseases 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• WWSNTLOVYSRDEL-DZSDEGEFSA-N compactin diol lactone Chemical compound C([C@@H]1[C@H]2[C@@H](O)CCC=C2C=C[C@@H]1C)C[C@@H]1C[C@@H](O)CC(=O)O1 WWSNTLOVYSRDEL-DZSDEGEFSA-N 0.000 description 1
• 238000010968 computed tomography angiography Methods 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical group NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
• 239000000287 crude extract Substances 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000005786 degenerative changes Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
• 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• WWSNTLOVYSRDEL-UHFFFAOYSA-N desmethylmonacolin J Natural products CC1C=CC2=CCCC(O)C2C1CCC1CC(O)CC(=O)O1 WWSNTLOVYSRDEL-UHFFFAOYSA-N 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 230000002542 deteriorative effect Effects 0.000 description 1
• 238000011847 diagnostic investigation Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000015872 dietary supplement Nutrition 0.000 description 1
• 238000003748 differential diagnosis Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 208000028659 discharge Diseases 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 238000009556 duplex ultrasonography Methods 0.000 description 1
• 206010013932 dyslexia Diseases 0.000 description 1
• 238000002592 echocardiography Methods 0.000 description 1
• 230000001819 effect on gene Effects 0.000 description 1
• 238000002297 emergency surgery Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 238000009585 enzyme analysis Methods 0.000 description 1
• 229960001208 eplerenone Drugs 0.000 description 1
• JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 108010091897 factor V Leiden Proteins 0.000 description 1
• 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 210000000497 foam cell Anatomy 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 208000037834 fusiform aneurysm Diseases 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 201000006408 generalized atherosclerosis Diseases 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
• 208000003906 hydrocephalus Diseases 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 208000029498 hypoalphalipoproteinemia Diseases 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 101150030475 impact gene Proteins 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 208000021156 intermittent vascular claudication Diseases 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 description 1
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
• 102000003835 leukotriene receptors Human genes 0.000 description 1
• 108090000146 leukotriene receptors Proteins 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 201000002818 limb ischemia Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000008752 local inflammatory process Effects 0.000 description 1
• 238000007477 logistic regression Methods 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 239000003055 low molecular weight heparin Substances 0.000 description 1
• 229940127215 low-molecular weight heparin Drugs 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• NXZVXXACWZJUDZ-UHFFFAOYSA-N methyl 3-[methyl-[3-[4-(thiophen-2-ylmethyl)phenoxy]propyl]amino]propanoate Chemical compound C1=CC(OCCCN(C)CCC(=O)OC)=CC=C1CC1=CC=CS1 NXZVXXACWZJUDZ-UHFFFAOYSA-N 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 229960002237 metoprolol Drugs 0.000 description 1
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
• 229950009116 mevastatin Drugs 0.000 description 1
• BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 208000006887 mitral valve stenosis Diseases 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• SHSJNKJJJLNOHA-UHFFFAOYSA-N n-(benzenesulfonyl)-3-[3-(4-benzylphenoxy)propyl-methylamino]propanamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(=O)CCN(C)CCCOC(C=C1)=CC=C1CC1=CC=CC=C1 SHSJNKJJJLNOHA-UHFFFAOYSA-N 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 238000007857 nested PCR Methods 0.000 description 1
• 238000002610 neuroimaging Methods 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 108091027963 non-coding RNA Proteins 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• 238000007826 nucleic acid assay Methods 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 229940012843 omega-3 fatty acid Drugs 0.000 description 1
• 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
• 239000006014 omega-3 oil Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 230000008289 pathophysiological mechanism Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 238000001558 permutation test Methods 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 210000004214 philadelphia chromosome Anatomy 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 229960002797 pitavastatin Drugs 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 210000003137 popliteal artery Anatomy 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 238000009117 preventive therapy Methods 0.000 description 1
• 208000032666 primary 1 hypoalphalipoproteinemia Diseases 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 238000000734 protein sequencing Methods 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 238000000611 regression analysis Methods 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 102210017646 rs2383208 Human genes 0.000 description 1
• 102210038592 rs4977575 Human genes 0.000 description 1
• 102210005693 rs564398 Human genes 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 238000013515 script Methods 0.000 description 1
• 230000009863 secondary prevention Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000005204 segregation Methods 0.000 description 1
• 230000009758 senescence Effects 0.000 description 1
• 208000018316 severe headache Diseases 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• LXZBFUBRYYVRQJ-AXHZAXLDSA-M sodium;(3r,5r)-7-[(1s,2s,6r,8s,8ar)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C=C21 LXZBFUBRYYVRQJ-AXHZAXLDSA-M 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000011895 specific detection Methods 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 108010003641 statine renin inhibitory peptide Proteins 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000000528 statistical test Methods 0.000 description 1
• 229930002534 steroid glycoside Natural products 0.000 description 1
• 150000008143 steroidal glycosides Chemical class 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000009752 translational inhibition Effects 0.000 description 1
• 230000017105 transposition Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 230000001228 trophic effect Effects 0.000 description 1
• 239000000225 tumor suppressor protein Substances 0.000 description 1
• 230000005760 tumorsuppression Effects 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 238000012285 ultrasound imaging Methods 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 238000007631 vascular surgery Methods 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 230000005186 women's health Effects 0.000 description 1
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical group C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
• 229960005332 zileuton Drugs 0.000 description 1